Streetwise Expert Interviews

Matthijs Smith

Six Innovative Australian Opportunities from Canaccord's Matthijs Smith

Canaccord Genuity's man on the beat in Australia delivers the insider scoop on how biotechs Down Under are faring in the markets. Matthijs Smith reveals a world of great firms, new products and competitive buys in this interview with the The Life Sciences Report. His enthusiasm for his work—spotting opportunities that help people cope with illness and injury—is contagious, and could bring renewed vigor to investors' portfolios. (8/28/14) More >


Yale Jen

Laidlaw's Yale Jen: Biotech 101 for Buyers and Sellers

Former biotech consultant Yale Jen picked up a few tricks advising companies on their pipelines before he came to Wall Street as a sellside analyst. These days Jen, managing director and senior biotechnology analyst at Laidlaw & Co., advises institutional investors to own stocks with stories that are not yet well understood by the market. In this interview with The Life Sciences Report, Jen offers investors a handful of names for consideration, each of which has an exceptional value proposition and exciting growth prospects. (8/28/14) More >


Read more Streetwise Interviews. . .

including Medtech Shifts from High Gear into Overdrive: Canaccord's William Plovanic (8/19/14) More >


Read more Streetwise Interviews. . .

including Wedbush Securities' Liana Moussatos on the Art and Science of Picking Biotechs with Upside (8/18/14) More >

Newsletter Briefs

"IPD's device allows the physician to detect lymphedema 200 days earlier than with a tape measure." (8/28/14) ImpediMed Ltd. - The Life Sciences Report Interview with Matthijs Smith More >

"There's more to OMER than Omidria; the company has quite a pipeline." (8/21/14) Omeros Corp. - The Life Sciences Report interview with Liana Moussatos More >

"MDXG provides better, faster and cheaper technology compared to current wound-care therapies." (8/19/14) MiMedx Group Inc. - William Plovanic, Canaccord Genuity More >

"CUR has two very credible shots on goal." (8/13/14) Neuralstem Inc. - The Life Sciences Report Interview with Raghuram Selvaraju More >

"ARNI's onapristone could potentially be a suprabillion-dollar drug upon approval." (8/13/14) Arno Therapeutics Inc. - The Life Sciences Report Interview with Raghuram Selvaraju More >

"RP is at the forefront of the utilization of stem cells to treat disorders and defects." (8/7/14) RepliCel Life Sciences Inc. - The Life Sciences Report Interview with Mark Landy More >

"A rapid and economical test like AMBS' LymPro could be used to improve Alzheimer's patient enrollment for future clinical trials." (8/6/14) Amarantus BioScience Holdings Inc. - Jason Napodano, Seeking Alpha More >

"Initial interim data from the Phase 1/2 study with STEM's HuCNS-SC cells in geographic atrophy age-related macular degeneration were extraordinarily encouraging." (7/31/14) StemCells Inc. - The Life Sciences Report Interview with Christopher James More >

Expert Analysis

"MSB ended H1/14 with $196M on the balance sheet." (8/26/14) Mesoblast Ltd. - Jason Kolbert, Maxim Group More >

"Results from STEM's Phase 1/2 dry AMD trial are compelling." (8/26/14) StemCells Inc. - Jolene Furdek, Edison Investment Research More >

"IMNP has enormous upside potential; it is one of our top ideas." (8/25/14) Immune Pharmaceuticals Inc. - Jason Napodano, Zacks Small-Cap Research More >

"For NEO, we expect test volume growth of ~25% in 2014, ~18% in 2015." (8/21/14) NeoGenomics Laboratories - Debjit Chattopadhyay, ROTH Capital Partners More >

"TRUU's licensing agreements with Disney and Marvel add the 'wow' factor." (8/20/14) True Drinks Inc. - Streetwise Reports' Special Situations Interview with Jim Collins More >

"We continue to remain optimist on CGIX in the near to medium term." (8/14/14) Cancer Genetics Inc. - Sung Ji Nam, Cantor Fitzgerald More >

"RXII could report preliminary data over the next four to six months." (8/15/14) RXi Pharmaceuticals Corp. - Reni Benjamin, H.C. Wainwright & Co. More >

"INO is reviewing final VGX-3100 data for presentation to the FDA." (8/11/14) Inovio Pharmaceuticals Inc. - Jason Kolbert, Maxim Group More >